Fluoropropyl-Trimethoprim
Phase 1Small molecule
Fluoropropyl-Trimethoprim is one of 5 small molecule programs targeting Relapsed or Refractory Follicular Lymphoma. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Relapsed or Refractory Follicular Lymphoma
#DrugCompanyPhaseTrials
1LUNSUMIO
RochePhase 3
Rituxan
RochePhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tociluzumab
RochePhase 3
Fluoropropyl-Trimethoprim
UUniversity of Pennsylvania
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluoropropyl-Trimethoprim. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pennsylvania